Charles River Laboratories Intl. Inc vs Rigetti Computing Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Rigetti Computing Inc trades at $14.03 (market cap $4.72B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 3× Rigetti Computing Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Rigetti Computing Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Rigetti Computing Inc for 35 Days on average.
| CRL | RGTI | |
|---|---|---|
Market Cap | $14.23B | $4.72B |
Volume | 1,176,885 | 17,136,381 |
Sector | Health | Technology |
52-Week High | $310.77 | $56.34 |
52-Week Low | $149.93 | $12.90 |
Typical Hold Time | 33 Days | 35 Days |
Enterprise Value | $17.06B | $4.33B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $301.79, up 0.5% with strong analyst support (73% buy ratings) and a $305.50 consensus target. The stock shows bullish technical momentum above key support levels, though fundamentals reveal challenges with negative net income margins (-5.96%) and elevated P/E ratio (684.85). Recent quarterly earnings beats and a new 2030 growth strategy provide optimism, but profitability concerns persist amid flat revenue trends.
The outlook balances near-term technical strength against fundamental headwinds. Investment opportunity lies in execution of the 5-7% growth target and $300M savings plan, while risks include sustained negative profitability, high debt levels ($2.24B), and margin pressure. Current price near resistance at $304 suggests limited upside without fundamental improvement.
RGTI trades at $14.03, down 3.84% with bearish technical signals despite bullish oscillators. The company shows minimal revenue of $7.09M (2025) with significant losses (-$216.21M net income) and negative margins. Analyst consensus remains strong with 85.71% buy ratings and $21.67 price target, while recent news highlights quantum computing sector momentum and Rigetti's hybrid quantum-HPC partnerships.
RGTI presents high-risk speculative potential with Wall Street optimism contrasting weak fundamentals. The stock offers substantial upside to analyst targets but faces execution risks in commercializing quantum technology amid persistent cash burn and competitive pressures from better-funded peers.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →